# MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC

> **NCT04633564** · PHASE3 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 671 (actual)

## Conditions studied

- NSCLC Stage IV

## Interventions

- **BIOLOGICAL:** Bevacizumab as MYL-1402O
- **BIOLOGICAL:** Bevacizumab as Avastin

## Key facts

- **NCT ID:** NCT04633564
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-21
- **Primary completion:** 2019-06-05
- **Final completion:** 2019-11-22
- **Target enrollment:** 671 (ACTUAL)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04633564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04633564, "MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04633564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*